U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07411586) titled 'Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia' on Feb. 11.
Brief Summary: The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes.
The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 can help to control the disease.
The safety and effects of this combination will also be studied in both parts.
Study Start Date: Aug. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Intervention:
DRUG: Zi...